Illumina (ILMN)
(Delayed Data from NSDQ)
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.00 -0.02 (-0.01%) 5:00 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.00 -0.02 (-0.01%) 5:00 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
by Zacks Equity Research
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
5 Winning Stocks With Superb Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: Caterpillar, WellCare Health, Intuit, Cardtronics and Illumina
Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View
by Zacks Equity Research
Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.
5 Top Stocks Showing Promise of an Earnings Beat
by Zacks Equity Research
Bet on five stocks that are likely to outdo earnings estimates.
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
4 Top Efficient Stocks to Buy for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.
Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.
Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.
Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.
Illumina Banks on Product Launches & Strategic Partnerships
by Zacks Equity Research
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
Illumina Banks on Strategic Partnerships, Competition Rife
by Zacks Equity Research
Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.
Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance
by Zacks Equity Research
Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.
Why Illumina (ILMN) Might Surprise This Earnings Season
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines
by Zacks Equity Research
Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Pacific Biosciences Hurt by Competition in Niche Markets
by Zacks Equity Research
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session
by Zacks Equity Research
Illumina (ILMN) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
Product Innovation Drives Illumina, Downbeat Margins a Woe
by Zacks Equity Research
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) banks on product launches and international market prospects.
Top Analyst Reports for Home Depot, Boeing & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Boeing (BA) and Merck (MRK).
Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx
by Zacks Equity Research
Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.